1
|
Janowska S, Holota S, Lesyk R, Wujec M. Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs. Molecules 2024; 29:346. [PMID: 38257259 PMCID: PMC10819800 DOI: 10.3390/molecules29020346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Revised: 01/04/2024] [Accepted: 01/08/2024] [Indexed: 01/24/2024] Open
Abstract
Aromatase is an enzyme that plays a crucial role in the biosynthesis of estrogens, which are hormones that contribute to the growth of certain types of breast cancer. In particular, aromatase catalyzes the conversion of androgens (male hormones) into estrogens (female hormones) in various tissues, including the adrenal glands, ovaries, and adipose tissue. Given the role of estrogen in promoting the growth of hormone-receptor-positive breast cancers, aromatase has become an important molecular target for the development of anticancer agents. Aromatase inhibitors can be classified into two main groups based on their chemical structure: steroidal and non-steroidal inhibitors. This work presents a review of the literature from the last ten years regarding the search for new aromatase inhibitors. We present the directions of search, taking into account the impact of structure modifications on anticancer activity.
Collapse
Affiliation(s)
- Sara Janowska
- Department of Pathobiochemistry and Interdisciplinary Applications of Ion Chromatography, Biomedical Sciences, Medical University of Lublin, 1 Chodzki Street, 20-093 Lublin, Poland
| | - Serhii Holota
- Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine; (S.H.); (R.L.)
| | - Roman Lesyk
- Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine; (S.H.); (R.L.)
| | - Monika Wujec
- Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, 4A Chodzki Street, 20-093 Lublin, Poland
| |
Collapse
|
2
|
Design, synthesis, in vitro and in silico studies of some novel triazoles as anticancer agents for breast cancer. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2021.131198] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Giampietro L, Gallorini M, Gambacorta N, Ammazzalorso A, De Filippis B, Della Valle A, Fantacuzzi M, Maccallini C, Mollica A, Cataldi A, Nicolotti O, Amoroso R. Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors. Eur J Med Chem 2021; 224:113737. [PMID: 34365129 DOI: 10.1016/j.ejmech.2021.113737] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 07/29/2021] [Accepted: 08/01/2021] [Indexed: 12/11/2022]
Abstract
The exploration of innovative aromatase inhibitors represents an important approach for the identification of new therapeutic treatments of breast cancer. In this respect, a series of phenyldiazenyl sulfonamides was designed, synthesized and tested. Compounds 3b, 3f and 5f showed an aromatase inhibition in the micromolar range and were evaluated in vitro on the human breast cancer cell line MCF7 by MTT assay, cytotoxicity assay (LDH release), cell cycle analysis and apoptosis, revealing a dose-dependent inhibition profile. In particular, 3f displayed the best reduction in terms of metabolic activity and an anti-proliferative effect on MCF7 cells, being blocked in the G1/S phase checkpoint. Moreover, computational studies were carried out to better understand at a molecular level of detail the rationale behind the effective binding to the active site of aromatase of the more active inhibitor 3f. The obtained results allow to consider this compound as an interesting lead for the development of a new class of non-steroidal aromatase inhibitors.
Collapse
Affiliation(s)
- Letizia Giampietro
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy.
| | - Marialucia Gallorini
- Unit of Anatomy, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Nicola Gambacorta
- Department of Pharmacy-Drug Science, University of Bari "Aldo Moro", Via E. Orabona, 4, 70126, Bari, Italy
| | - Alessandra Ammazzalorso
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Barbara De Filippis
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Alice Della Valle
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Marialuigia Fantacuzzi
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Cristina Maccallini
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Adriano Mollica
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Amelia Cataldi
- Unit of Anatomy, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| | - Orazio Nicolotti
- Department of Pharmacy-Drug Science, University of Bari "Aldo Moro", Via E. Orabona, 4, 70126, Bari, Italy
| | - Rosa Amoroso
- Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, Chieti, Italy
| |
Collapse
|
4
|
Rani S, Raheja K, Luxami V, Paul K. A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors. Bioorg Chem 2021; 113:105017. [PMID: 34091288 DOI: 10.1016/j.bioorg.2021.105017] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Revised: 05/15/2021] [Accepted: 05/20/2021] [Indexed: 12/11/2022]
Abstract
Breast cancer, emerging malignancy is common among women due to overexpression of estrogen. Estrogens are biosynthesized from androgens by aromatase, a cytochrome P450 enzyme complex, and play a pivotal role in stimulating cell proliferation. Therefore, deprivation of estrogen by blocking aromatase is considered as the effective way for the inhibition and treatment of breast cancer. In recent years, various non-steroidal heterocyclic functionalities have been extensively developed and studied for their aromatase inhibition activity. This review provides information about the structural-activity relationship of heterocycles (Type II) towards aromatase. This aids the medicinal chemist around the significance of different heterocyclic moieties and helps to design potent aromatase inhibitors.
Collapse
Affiliation(s)
- Sudesh Rani
- School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala 147001, India
| | - Konpal Raheja
- School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala 147001, India
| | - Vijay Luxami
- School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala 147001, India
| | - Kamaldeep Paul
- School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala 147001, India.
| |
Collapse
|